Results 41 to 50 of about 2,193 (158)

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

IJTLD Open
Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug ...
L. Kuksa, C. Andrejak, B. Haecker, G. Bothamley, A. Calcagno, D.M. Cirillo, R. Duarte, R. Fatima, G. Ferlazzo, L. Guglielmetti, G. Günther, C. Hewison, C.R. Horsburgh, T. Jäger, Y. Kalancha, R. Otto-Knapp, K. Kranzer, T. Lillebaek, G. Marks, K. Middelkoop, I. Motta, V. Rabinova, P. Sommerfeld, P. Tattevin, C. Lange   +24 more
doaj   +1 more source

Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug‐Resistant Tuberculosis

Clinical Pharmacology &Therapeutics, EarlyView.
Pretomanid is a component of the World Health Organization‐recommended treatment regimen for drug‐resistant tuberculosis in patients aged ≥ 14 years. While preclinical rodent studies identified testicular toxicity as a potential clinical liability at elevated doses, no corresponding effects were observed in nonhuman primates nor clinical hormone ...
Pauline Howell, Antonio Lombardi, William Brumskine, Lali Mikiashvili, Kim Boekelheide, Joanna Moreira, Alda Holsta, Matthew Betteridge, Lindsay Thompson, Angela Crook, Paul Bruinenberg, Maria Beumont, Eugene Sun, Francesca Conradie   +13 more
wiley   +1 more source

The Mycobacterium tuberculosis Rv0132c Gene Product Mtb‐FGD2 Can Act as an F420‐Dependent Glucose Dehydrogenase

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT The role of the cell envelope‐associated Rv0132c/FGD2 from Mycobacterium tuberculosis has long been a subject of debate. Importantly, FGD2 is found only in pathogenic mycobacteria, making it a potential drug target. While some suggest it functions as a glucose‐6‐phosphate dehydrogenase, others propose it acts instead as an F420‐dependent ...
Adewale V. Aderemi, Matthew Snee, Richard B. Tunnicliffe, Linus O. Johanissen, Matthew J. Cliff, Colin W. Levy, Derren J. Heyes, Marina Golovanova, Thomas A. Jowitt, Sam Hay, Andrew W. Munro, Jonathan P. Waltho, David Leys   +12 more
wiley   +1 more source

Savings from the introduction of BPaL and BPaLM regimens at the country level

IJTLD Open
BACKGROUND: In 2022, the WHO recommended the 6-month regimens BPaL (bedaquiline + pretomanid + linezolid) and BPaLM (BPaL + moxifloxacin) as treatment options for most forms of drug-resistant TB.
C. Auer, A. Gupta, C. Malbacius, A. Ghafoor, Y. Kock, O. Medvedieva, P. Hanlon, P. Steinmann, S. Juneja   +8 more
doaj   +1 more source

Clostridioides difficile as a Zoonotic and Foodborne Pathogen: Reviewing the Global Evidence and South African Data

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Clostridioides difficile infections are increasingly problematic in areas with already burdened healthcare systems. From a One‐Health perspective, a lack of surveillance in developing countries greatly contributes to the limited information available on the zoonotic and foodborne potential of C. difficile.
M. Gouws, P. E. Strydom, D. Rip
wiley   +1 more source

Clinically Approved Antibiotics from 2010 to 2022

CHIMIA, 2023
This review discusses small molecule antibiotics approved for clinical use in the time frame 2010-2022. This time span saw the approval of four synthetic antibiotics (bedaquiline, pretomanid, delafloxacin, tedizolid), nine natural product derivatives ...
Erik Jung, Karl Gademann
doaj   +1 more source

Thiazolidinedione–Pyrazolopyrimidinone Molecular Hybrids With Alkyl Spacers: Potential Antitubercular Agents Complemented by Molecular Modeling

ChemistrySelect, Volume 11, Issue 24, 25 June 2026.
We report the synthesis of 21 novel thiazolidinedione–pyrazolopyrimidinone derivatives (12a–u), prepared by coupling thiazolidinedione and pyrazolopyrimidinone pharmacophores through various alkyl linkers. The compounds were characterized spectroscopically and evaluated against the Mtb H37Rv strain, identifying compounds 5c and 5d as potent ...
Pule Seboletswe, Gobind Kumar, Nontobeko Gcabashe, Sanjeev Dhawan, Neha Manhas, Ankit, Audrey Jordaan, Digby F. Warner, Parvesh Singh   +8 more
wiley   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1205-1215, May 2026.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Genetic Aspects of Mycobacterium Tuberculosis Resistance to New Anti-Tuberculosis Drugs

Туберкулез и болезни лёгких, 2023
We analyzed 57 publications devoted to study of genetic mechanisms of formation of drug resistance of Mycobacterium tuberculosis to bedaquiline, delamanid, pretomanid, linezolid, and clofazimine.
A. V. Kukurika, E. I. Veselova, A. B. Peregudova   +2 more
doaj   +1 more source

Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Tuberculosis (TB) remains a major global health problem, and treatment progress is increasingly threatened by rising multidrug‐resistant tuberculosis (MDR‐TB). Delamanid (DLM), a nitroimidazole drug, has shown good efficacy and safety against both drug‐susceptible and drug‐resistant Mycobacterium tuberculosis (Mtb) strains.
Md. Mahmudul Islam, Md. Zahid Hasan, Md. Touki Tahamid Tusar, Md. Yeamin Hossain, Md. Motaher Hossain, Md. Abdulla Al Jubayed, Md. Jubaer‐Al‐Abedin, Sheikh Soikot, Shanzida Akther, Jahid Bhuyian, Hafizur Rahman Gazi, B. M. Mahmudul Hasan, Md. Shofiul Azam, Md. Enamul Haque, Abdullah‐Al‐Jubayer, Md. Faruk Hasan, F. M. Ali Haydar, Md. Khalekuzzaman, Md. Torequl Islam, Sohel Hasan   +19 more
wiley   +1 more source